Protocol Ledger

NCT06533098 · Phase III · RECRUITING

A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Interventional Phase III clinical trial protocol NCT06533098 sponsored by Johnson & Johnson / Janssen in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-02-10 Enrollment: 50 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06533098
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)50 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06533098
Protocol FieldVerified Registry Value
NCT IdentifierNCT06533098
Consolidated Lead SponsorJohnson & Johnson / Janssen
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment50 participants (ESTIMATED)
Registered Start Date2025-02-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06533098
Hospital Research SiteLocationSite Profile
UC Davis Comprehensive Cancer CenterSacramento, CAOpen Hospital Dossier ->
University of Rochester Medical CenterRochester, NYOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI